Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Interest Expenses (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Interest Expenses for 8 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest Expenses fell 6.5% year-over-year to $2.3 million, compared with a TTM value of $9.0 million through Sep 2025, up 7.71%, and an annual FY2024 reading of $8.8 million, up 51.77% over the prior year.
  • Interest Expenses was $2.3 million for Q3 2025 at X4 Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.4 million in Q3 2024 and bottomed at $891000.0 in Q1 2021.
  • Average Interest Expenses over 5 years is $1.5 million, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Interest Expenses soared 89.55% in 2024, then decreased 6.5% in 2025.
  • Year by year, Interest Expenses stood at $925000.0 in 2021, then increased by 23.68% to $1.1 million in 2022, then skyrocketed by 64.86% to $1.9 million in 2023, then rose by 22.16% to $2.3 million in 2024, then fell by 2.04% to $2.3 million in 2025.
  • Business Quant data shows Interest Expenses for XFOR at $2.3 million in Q3 2025, $2.2 million in Q2 2025, and $2.2 million in Q1 2025.